<?xml version='1.0' encoding='utf-8'?>
<document id="26829173"><sentence text="Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers."><entity charOffset="0-12" id="DDI-PubMed.26829173.s1.e0" text="Ketoconazole" /></sentence><sentence text="Ketoconazole is a potent CYP3A inhibitor in vivo, and frequently serves as an index CYP3A inhibitor in drug-drug interaction (DDI) studies with healthy volunteers"><entity charOffset="0-12" id="DDI-PubMed.26829173.s2.e0" text="Ketoconazole" /></sentence><sentence text=" Limitations restricting the use of systemic ketoconazole in such studies have been recently imposed by regulatory agencies in the United States, the European Union, and elsewhere"><entity charOffset="45-57" id="DDI-PubMed.26829173.s3.e0" text="ketoconazole" /></sentence><sentence text=" A risk of ketoconazole-associated liver injury in the context of DDI studies was cited as the primary justification for these measures"><entity charOffset="11-23" id="DDI-PubMed.26829173.s4.e0" text="ketoconazole" /></sentence><sentence text=" To evaluate the basis for these restrictions, we analyzed a series of published DDI studies identified from a review of existing literature" /><sentence text=" The study set consisted of 53 DDI studies, and included 971 healthy volunteers with systemic ketoconazole exposure in addition to the victim drug under study"><entity charOffset="94-106" id="DDI-PubMed.26829173.s6.e0" text="ketoconazole" /></sentence><sentence text=" Ketoconazole-associated abnormalities in serum chemistry values indicative of liver injury were observed in 4 subjects, representing a prevalence of 0"><entity charOffset="1-13" id="DDI-PubMed.26829173.s7.e0" text="Ketoconazole" /></sentence><sentence text="41% within the study population" /><sentence text=" There were no major adverse reactions or instances of hepatic failure" /><sentence text=" All abnormalities indicative of liver injury resolved upon discontinuation of ketoconazole treatment"><entity charOffset="79-91" id="DDI-PubMed.26829173.s10.e0" text="ketoconazole" /></sentence><sentence text=" The findings from this review do not support restriction of ketoconazole as an index CYP3A inhibitor in DDI studies involving healthy volunteers"><entity charOffset="61-73" id="DDI-PubMed.26829173.s11.e0" text="ketoconazole" /></sentence><sentence text="" /></document>